Press Release: OyaGen : New Market Report: OyaGen Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

(PR-inside.com) OyaGen Inc. (OyaGen) is a biotechnology company. The company discovers, develops and commercializes pharmaceutical therapies. Its products include Vif dimerization antagonist, Vif interaction with APOBEC3G, Vif dependent polyubiquitination of APOBEC3G, APOBEC3G activators. The company offers pharmaceutical therapies to exploit RNA editing and DNA editing enzymes. OyaGen has identified two families of editing enzymes. It pursues several assays in high throughput screening strategies for drug development. The company's editing enzyme hA3G serves as natural defense against HIV-1 infection. Its technology platform includes family of fourteen editing enzymes and the proteins that modulate their activity. OyaGen is headquartered in Henrietta, New York, ..